Conference Presentation, Fireside Chat, Panel
A Conversation with FDA Commissioner Scott Gottlieb
- Sleep deprivation in children is projected to worsen due to the prevalence of cell phones and TVs in bedrooms, while total sleep hours in the U.S. population are expected to continue decreasing over time.
- Inadequate sleep is linked to increased hunger hormones, calorie intake, weight gain, and obesity, with the nation facing challenges in uniting to address obesity and lacking a simple solution despite hypothetical vaccine concepts.
- Community efforts to strengthen families, make healthy eating easier, and improve parenting strategies regarding screen time require increased investment, particularly as current messaging remains unclear and interactions among lower-income children need further study.
- Research investment is needed to determine effective school strategies for screen time, and the timeline between research and scaling solutions is expected to improve to accelerate the implementation of effective interventions.
- Significant scaling challenges exist in rural, urban, and low-income communities, requiring massive resources to diffuse interventions, with current efforts like the opioid response limited to four states due to high costs.
- To achieve scale, prevention efforts require continued or increased funding for the CDC, and larger investments are needed to expand initiatives like the pre-diabetes campaign to reach populations ranging from 5 million to 80 million people.
- The FDA expects to soon release specifications for generic alternatives to abuse-deterrent formulations and will provide testimony to Congress on medically assisted treatments and incentives for better MAT products.
- Enforcement strategies involve collaboration with Customs and Border Patrol and the USPS to address the overwhelming volume of packages containing illicit substances.
- The FDA intends to regulate nicotine content in combustible cigarettes to render them minimally addictive and aims to significantly reduce the rate of combustible cigarette addiction within a reasonable timeframe.
- Application deadlines for non-combustible nicotine delivery forms, such as e-cigarettes, are expected to be extended to allow for innovation, while existing regulations will continue to restrict minor access, enforce labeling, and ban appealing flavors.
- A regulatory pathway is expected to be developed to facilitate product innovation in medicinal nicotine forms like patches and gums, mirroring trends observed in European markets.
- AI algorithms with sufficient data are projected to eventually outperform most humans in medical diagnostics, prompting the FDA to reimagine regulatory frameworks for novel technologies and cell-based therapies.
- The FDA expects to request additional congressional authority regarding laboratory-developed tests to establish distinct regulatory frameworks for emerging technologies.